Read 3 articles daily and stand to win ST rewards, including the ST News Tablet worth $398.
Spin the wheel for ST Read and Win now.
Singapore-based biotechnology firm Tessa Therapeutics (Tessa) has come a long way from the Singapore cafe where the idea of its inception was hatched.
Born over a discussion eight years ago between an immunologist and an oncologist, it is today ahead in the race to turn cancer patients' own immune cells (T-cells) against the tumours in their bodies.
Please subscribe or log in to continue reading the full article.
*Terms and conditions apply.
Join ST's Telegram channel here and get the latest breaking news delivered to you.
We have been experiencing some problems with subscriber log-ins and apologise for the inconvenience caused. Until we resolve the issues, subscribers need not log in to access ST Digital articles. But a log-in is still required for our PDFs.